Vident Investment Advisory, LLC Hutchmed (China) LTD Transaction History

Vident Investment Advisory, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$28.89 - $35.33 $170,335 - $208,305	-5,896 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$35.66 - $42.94 $70,321 - $84,677	-1,972 Reduced 25.06%	5,896 $216,000
Q1 2021 May 14, 2021	BUY	$27.01 - $36.8 $783 - $1,067	29 Added 0.37%	7,868 $222,000
Q4 2020 Feb 08, 2021	SELL	$27.51 - $34.36 $935 - $1,168	-34 Reduced 0.43%	7,839 $251,000
Q3 2020 Nov 12, 2020	SELL	$25.8 - $34.61 $50,826 - $68,181	-1,970 Reduced 20.01%	7,873 $254,000
Q2 2020 Jul 17, 2020	SELL	$17.65 - $28.05 $46,313 - $73,603	-2,624 Reduced 21.05%	9,843 $271,000
Q1 2020 May 12, 2020	SELL	$15.19 - $29.51 $34,526 - $67,076	-2,273 Reduced 15.42%	12,467 $223,000
Q4 2019 Feb 11, 2020	BUY	$17.17 - $25.95 $74,225 - $112,181	4,323 Added 41.5%	14,740 $370,000
Q3 2019 Nov 13, 2019	BUY	$17.84 - $22.69 $185,839 - $236,361	10,417 New	10,417 $186,000

8.25M

3.8K

2.4K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $3.11B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Investment Advisory, LLC with notifications on news.